本帖最后由 老马 于 2013-3-13 13:43 编辑 % u' I' K2 v% e7 ], Q. H. }, |
* |7 P; M( z: t- M
健择（吉西他滨）+顺铂+阿瓦斯汀# x6 I/ p3 O& ~
Gemzar +Cisplatin + Avastin
, W7 O2 O1 B* N$ lhttp://annonc.oxfordjournals.org/content/21/9/1804.full
8 w( L- A; C( uOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 5 U/ s/ M! Z% Z' S7 e: u4 @1 Q
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. # e# i1 D- p' S- _) Q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported. . U { E) t2 f, N( [9 z
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 942)
$ @" R' o/ i% V m t* z9 C. v
华为网盘附件：/ |+ k' O9 V5 V- |3 ]
【华为网盘】ava.JPG
3 x$ |- N+ g7 ~3 E& @ |
显身卡
